Can Creatine Support Mood? A Careful Look at the Early Research

A note on this article: Creatine has been discontinued from the Proco range — the current lineup is Cognitive Support, Sleep Support, Sleep Formula, Omega-3 and Magnesium Glycinate. We're keeping the research below live because it's still accurate and useful — you just won't find Creatine in our shop.

Creatine's reputation was built on the gym floor and, more recently, on cognitive-performance research — strength, power output, and short-term memory under fatigue or sleep loss. Over the past decade, a smaller and much less settled body of research has asked a different question: could creatine also play a role in mood? Specifically, could it help as an add-on to standard antidepressant treatment for depression?

The honest answer, right now, is: maybe, in a narrow and unproven way — and the research is genuinely early. We're talking about a handful of small trials, some with contradictory results, testing creatine as an addition to prescribed antidepressant treatment, not as a replacement for it. Depression is a medical condition that needs professional diagnosis and care. Nothing below changes that.

Corrected September 2026: three fixes. (1) An earlier version put a sentence in quotation marks as the 2025 meta-analysis's "topline finding" that does not appear in that paper. It has been replaced with the authors' actual wording. (2) We said its benefit "essentially disappeared when the analysis was restricted to the highest-quality, lowest-bias trials." What the authors report is that subgroup analyses and trim-and-fill adjustments indicated substantial bias favouring creatine — a related but different claim, now stated as they state it. (3) We reported the 2018 bipolar trial's null primary outcome but omitted that it found a significant advantage on remission, a secondary outcome. Both results are below.

This is a different evidence base than creatine and cognition

It's worth being precise about this, because the two topics get blurred constantly online. Creatine's cognitive-performance research — effects on working memory and mental fatigue, particularly under sleep deprivation or in vegetarians with lower baseline creatine stores — rests on a larger and more consistent set of controlled trials. We've covered that evidence in detail in Creatine and the Brain: What the Cognitive Research Actually Shows, and the broader picture in our complete creatine guide.

Creatine and depression is a separate, newer, and much smaller research thread. It comes out of a specific scientific idea — brain bioenergetics — rather than out of a large stack of replicated clinical trials. That distinction matters, so we're keeping the two topics apart here rather than letting one borrow credibility from the other.

The theory: why researchers are even asking this question

The starting point is basic neuroscience. Creatine, once inside cells, converts to phosphocreatine, which acts as a rapid-access energy reserve — a buffer the brain draws on when demand for ATP spikes. Some researchers have proposed that impaired brain energy metabolism is involved in depression, and that boosting phosphocreatine availability might support neurons under that kind of energetic strain. This is often called the "bioenergetics" or "phosphocreatine" hypothesis of depression.

It's a plausible mechanism, not a proven one. A 2016 dose-ranging trial by Kondo and colleagues, using phosphorus-31 magnetic resonance spectroscopy to directly measure brain phosphocreatine in adolescent females with SSRI-resistant depression, found that higher creatine doses (up to 10g/day) did raise frontal-lobe phosphocreatine levels, and that higher phosphocreatine correlated with lower depression severity scores. That's a real, measurable biological signal — but a correlation between a brain metabolite and symptom scores in one small trial is evidence of a mechanism worth studying, not evidence of a treatment that works. A compelling mechanism also makes a small trial feel more convincing than its size warrants, which is worth reading alongside what the placebo effect in supplements actually means.

2.2 pts

The depression-score improvement found in a 2025 meta-analysis pooling 11 randomized trials and 1,093 participants — below the 3-point minimal important difference on the 17-item Hamilton scale, with a confidence interval reaching −0.00 and very low certainty of evidence. Eckert et al., British Journal of Nutrition, 2025

What the clinical trials actually show

The most cited positive result comes from a 2012 randomized, double-blind, placebo-controlled trial published in the American Journal of Psychiatry (Lyoo et al.). It enrolled 52 women with major depressive disorder who were starting the SSRI escitalopram, and randomized them to add either 5g/day of creatine (n=25) or placebo (n=27) for 8 weeks. The creatine group showed significantly greater improvement in Hamilton Depression Rating Scale scores as early as week 2, with the advantage maintained at weeks 4 and 8. Two details for balance: dropout was higher in the creatine arm (32.0% vs 18.5%, not a statistically significant difference), and overall adverse-event frequency was similar between groups. It's a genuinely interesting result — but it's one trial, in one narrow population (adult women, one specific SSRI), that hasn't been closely replicated at that scale.

Other trials have not been as encouraging. A 2013 dose-finding pilot study (Nemets & Levine, International Clinical Psychopharmacology) added 5g or 10g/day of creatine, versus placebo, to ongoing antidepressant treatment in 18 patients with treatment-resistant depression over 4 weeks. It found no overall advantage for creatine at either dose — though two of the women on creatine did show an early, sizeable response, hinting at a possible subgroup effect that would need a much larger trial to confirm or rule out.

There's also a caution worth flagging directly, and a mixed result inside it. A 2018 proof-of-concept trial testing creatine as an add-on for bipolar depression (Toniolo et al., Journal of Neural Transmission) randomized 35 patients already on regular medication to creatine monohydrate 6g/day (n=17) or placebo (n=18) for 6 weeks. On its primary outcome — change in the Montgomery-Åsberg Depression Rating Scale — there was no statistically significant difference between groups in intention-to-treat analysis (p=0.560, Cohen's d=0.231). On a secondary outcome, remission defined as a MADRS score of 12 or below at week 6, creatine was significantly superior: 52.9% remission versus 11.1% on placebo in ITT (p=0.012, OR=9.0), and 66.7% versus 18.2% among the 23 completers (p=0.036, OR=9.0). We previously reported only the null, which was one-sided of us. What doesn't change is the safety signal: two patients who received creatine switched to hypomania during the trial. Mood disorders aren't one condition, and what looks safe in one diagnosis isn't automatically safe in another — one more reason this isn't a "try it yourself" supplement decision.

A handful of small, inconsistent trials — with the pooled effect sitting just inside statistical significance and just outside clinical meaningfulness — is a reason to keep researching, not a reason to self-treat.

The 2025 verdict: a systematic review says "not yet"

The most useful recent read on this topic isn't a single trial — it's a 2025 systematic review and meta-analysis in the British Journal of Nutrition (Eckert, Lima & Dariva) that pooled 11 randomized controlled trials in 1,093 participants. The pooled standardised mean difference was −0.34 (95% CI −0.68 to −0.00) — an interval whose upper bound reaches zero — equivalent to 2.2 points on the 17-item Hamilton Depression Rating Scale, against a minimal important difference of 3.0 points. Heterogeneity was substantial (I²=71.3%), and the authors note the confidence interval includes non-clinically-important effects. While effects appeared larger in clinically depressed populations, subgroup analyses and trim-and-fill adjustments indicated substantial bias favouring creatine. Secondary endpoints were mixed: significant for remission (3 trials, OR 3.60, 95% CI 1.76–7.56) but not for treatment response (2 trials, OR 0.72, 95% CI 0.28–1.88). The authors graded the certainty of evidence very low, and their own summary is worth quoting accurately: creatine "may offer a small-to-moderate benefit for individuals with depression, but average effects were not clinically important and the true effect may be trivial or null."

That's the responsible summary of where this field actually stands in 2026: a plausible biological mechanism, one encouraging small trial, at least one null trial, one trial with a null primary and a significant secondary plus a bipolar-specific safety flag, and a fresh meta-analysis saying the pooled evidence is weak, possibly inflated by bias, and short of clinical meaningfulness. For a nutrient with a comparably thin adjunct literature handled the same way, see zinc and depression; for one with a much deeper base, omega-3 and depression.

What this means if you're being treated for depression

Every trial in this area tested creatine as an addition to standard antidepressant treatment, prescribed and monitored by a clinician — never as a replacement for it, and never in people who'd stopped their prescribed treatment. Depression is a medical condition, and diagnosis and treatment decisions belong with a doctor or licensed therapist, not with a supplement label. If you take an SSRI, SNRI, or another psychiatric medication and you're curious about creatine — for any reason, including its far better-established cognitive or strength-training uses — that's a conversation to have with your prescriber first. We go into more detail on that in Proco Products and Mental Health Medications: Interactions. If you're looking for something with a genuinely strong evidence base for depressive symptoms outside medication and therapy, the exercise trial data is where the numbers actually are.

Key takeaway: Creatine-as-mood-support is a genuinely early research area — a handful of small trials, one encouraging, one null, one with a null primary outcome and a significant secondary, and a 2025 meta-analysis whose pooled effect just reaches statistical significance, falls short of clinical meaningfulness, and is rated "very low" certainty with signs of bias favouring creatine. It has only been studied as an add-on to prescribed antidepressant treatment, never as a stand-alone or substitute therapy, and depression itself needs professional diagnosis and care.

Bottom line

Creatine's role in mood is one of the more interesting open questions in nutrition-psychiatry research right now, and it deserves more, larger, well-controlled trials. It does not yet deserve the confidence that creatine's cognitive-performance or strength-training research has earned. If you're managing depression or low mood, the evidence here isn't a reason to change, add to, or step back from prescribed treatment on your own — that decision belongs with a doctor or licensed therapist. Supplements, including creatine, are not a substitute for professional mental health care, which is the same conclusion we reach across the category in can supplements help with anxiety and low mood.

This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. If you are experiencing persistent low mood or depression, please talk to a doctor or licensed therapist — supplements are not a substitute for professional care.

References

Want to know what's actually in what you take? Join the list — no spam, just it straight.